Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program
TEL AVIV, Israel, March 14, 2018 /PRNewswire/ --áTASE analysis project was launched in 2016 in order to raise the investors' level of knowledge of TASE listed technology and life-science companies and the markets in which the companies operate, thus creating appropriate
In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with the TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and the TASE.
Summary of Highlights
About the company - RedHill Biopharma Ltd. ("the Company" and/or "RedHill") is an Israeli publicly-traded specialty biopharmaceutical company focused on the development and commercialization of late clinical-stage drugs candidates. The Company's main focus is advanced clinical development and commercialization in the US of orally-administered, proprietary, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill is currently promoting three gastrointestinal products and is advancing multiple clinical programs: three Phase III for gastrointestinal and inflammation indications and multiple Phase II for various indications including multiple myeloma, hepatocellular carcinoma, pancreatic cancer, and irritable bowel syndrome with diarrhea. please clickáhere (https://ww2.frost.com/research/equity-research/)
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: áStart the discussion
Kristi Cekaniá Corporate Communications - Frost & Sullivan, EuropeP: +39.02.4851.6133E: firstname.lastname@example.org http://www.frost.com
View original content:http://www.prnewswire.com/news-releases/frost--sullivan-publishes-update-coverage-report-on-redhill-biopharma-ltd-net-revenues-for-2017-met-expectations-at-4m-likely-capital-raising-in-mid-2018-when-phase-iii-results-for-crohns-disease-are-announced-price-target--300613782.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!